Conditions: Myeloid Leukemia, Chronic, Accelerated Phase Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Keywords: Accelerated Phase Chronic Myeloid Leukemia Lymphoid Blast Phase Chronic Myeloid Leukemia Myeloid Blast Phase Chronic Myeloid Leukemia Philadelphia Positive Acute Lymphoblastic Leukemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 638
Healthy volunteers: no

Brief summary:
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).

Detailed description:

Arms:
arm 1: 70 mg dasatinib twice a day (BID) arm 2: 140 mg dasatinib once a day (QD)

Interventions: intervention 1: dasatinib intervention 2: dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, 70 mg BID, indefinitely, survival study intervention 2: Tablets, Oral, 140 mg QD, indefinitely, survival study

Protocol document: